Overview
- The randomized, double-blind, placebo-controlled OASIS-4 trial assigned 307 adults with overweight or obesity to once-daily oral semaglutide 25 mg or placebo for 64 weeks.
- By week 64, 50% of participants on semaglutide achieved at least 15% weight loss compared with 5.6% on placebo.
- Within the semaglutide arm, participants who lost at least 15% of body weight had larger reductions in HbA1c, fasting plasma glucose and fasting insulin than those with smaller losses.
- Cardiovascular risk markers improved more with greater weight loss, including systolic and diastolic blood pressure (–10.1/–4.3 mm Hg vs –4.1/–1.1), as well as C-reactive protein, non‑HDL cholesterol and triglycerides.
- Among participants with prediabetes, normoglycemia at week 64 occurred in 71.1% on semaglutide vs 33.3% on placebo, and in 92.5% vs 54% for the ≥15% vs <15% weight‑loss subgroups within semaglutide; the post hoc findings were presented by Domenica Rubino, who reported no relevant financial disclosures, and the oral formulation is under FDA review for obesity.